How big is the diabetes diagnostics market today, and what are its future growth expectations?
The diabetes diagnostics market size has grown strongly in recent years. It will grow from $25.39 billion in 2024 to $27.39 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising prevalence of diabetes, expanding geriatric population, increase in sedentary lifestyles, increase in adoption of minimally invasive diagnostic, and rising prevalence of obesity.
The diabetes diagnostics market size is expected to see strong growth in the next few years. It will grow to $36.72 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to rising adoption of insulin pumps, increasing advancements in diabetes technology, rising in the adoption of unhealthy Lifestyles, surge in the prevalence of type 1 and type 2 diabetes, and expanding healthcare infrastructure. Major trends in the forecast period include advancements in biosensor technology, technological advancements, advancements in diagnostic technologies, personalized medicine and targeted therapies, and advanced technologies in in vitro diagnostic products.
Get Your Free Sample of The Global Diabetes Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21167&type=smp
What have been the primary factors driving the diabetes diagnostics market’s growth?
The higher prevalence of obesity is expected to propel the growth of the diabetes diagnostics market going forward. Obesity refers to an excessive accumulation of body fat that increases the risk of various health conditions, such as heart disease and diabetes. The higher prevalence of obesity is attributed to factors such as sedentary lifestyles, increased consumption of processed and high-calorie foods, genetic predisposition, and limited physical activity. Diabetes diagnostics support obesity management by identifying insulin resistance and glucose metabolism issues early, enabling timely interventions to prevent weight gain and related health complications. For instance, in September 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022, 22 states had an adult obesity rate of 35% or higher, an increase from 19 states in 2021. Therefore, the higher prevalence of obesity is driving the growth of the diabetes diagnostics market.
What are the key segments within the diabetes diagnostics market?
The diabetes diagnostics market covered in this report is segmented –
1) By Product Type: Blood Glucose Meters, Continuous Glucose Monitoring Devices, Lancets, Test Strips, Other Product Types
2) By Diabetes Type: Diabetes I, Diabetes II, Gestational Diabetes
3) By End-User: Hospitals, Diagnostic Centers, Homecare Settings, Other End-Users
Subsegments:
1) By Blood Glucose Meters: Traditional Blood Glucose Meters, Smart Blood Glucose Meters, Bluetooth-enabled Blood Glucose Meters
2) By Continuous Glucose Monitoring Devices: Wearable CGM Systems, Implantable CGM Systems, Flash Glucose Monitoring Devices
3) By Lancets: Single-use Lancets, Multi-use Lancets
4) By Test Strips: Standard Test Strips, Smart Test Strips
5) By Other Product Types: Hemoglobin A1c Testing Kits, Urine Glucose Test Strips, Blood Ketone Meters
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/diabetes-diagnostics-global-market-report
Which key players are shaping the diabetes diagnostics market?
Major companies operating in the diabetes diagnostics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Novartis AG, 3M Company, Medtronic plc, Regeneron Pharmaceuticals Inc., Carl Zeiss Meditec AG, Bausch & Lomb Incorporated, DexCom Inc, Santen Pharmaceutical Co. Ltd., Topcon Corporation, Tandem Diabetes Care Inc, Ypsomed AG, LifeScan Inc, Nova Biomedical Corporation, Ascensia Diabetes Care Holdings AG, ARKRAY Inc, Optos plc, Bioland Technology Ltd, PTS Diagnostics Inc, AgaMatrix Inc, Senseonics Holdings Inc, DarioHealth Corp.
How will emerging trends drive the diabetes diagnostics market throughout the forecast period?
Major companies operating in the diabetes diagnostics market are focused on developing innovative products such as gestational diabetes diagnostics tools to expand their product portfolios and meet the growing demand for early detection and management of diabetes during pregnancy. A gestational diabetes diagnostic tool refers to medical devices or tests used to detect and monitor gestational diabetes in pregnant women, typically involving blood glucose testing, such as the oral glucose tolerance test (OGTT), to assess how well the body processes sugar during pregnancy. For instance, in August 2024, DirectSens GmbH, an Austria-based biotechnology company, launched XpressGT RUO kit, a groundbreaking biosensor tool designed for the detection of insulin resistance-related conditions such as gestational diabetes, endometriosis, and liver disease. The kit provides rapid results, measuring 2-hydroxybutyrate (2-HB) levels in venous blood, and is compatible with standard clinical analyzers. This innovation aims to offer early diagnostics, potentially improving outcomes for millions of patients worldwide.
How do regional factors impact the diabetes diagnostics market, and which region is the largest contributor?
North America was the largest region in the diabetes diagnostics market in 2024. The regions covered in the diabetes diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Diabetes Diagnostics Market Report 2025 Offer?
The diabetes diagnostics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Diabetes diagnostics refers to the methods and tests used to identify and monitor diabetes by measuring blood glucose levels and other relevant biomarkers. It involves various medical assessments to detect abnormal glucose metabolism and assess the risk or presence of diabetes. Accurate diagnostics aid in early detection, disease management, and treatment planning.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21167
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
